Laboratorios Rubió is a company that is currently
undergoing a process of expansion and growth
(in thousands of €)
Laboratorios Rubió is a pharmaceutical company in a continuous process of business development, expansion, and growth. The ascending progression of turnover is an indicator of the good work done. Our strategic plan focuses on internationalization through partnering and R&D for developing new pharmaceutical drugs.
The turnover of 2023 totaled € 132 million, representing an annual increase of 22,4%. By markets, in Spain, the increase has been 23,24% and 18,57% internationally. For 2024, we expect to continue the growth in turnover and reach 167M€, which accounts for a 27% increase.
The company’s team is composed of 269 people in 2023—75% more than in 2019—with the greatest amount of growth in the sales and industrial operations departments.
At Laboratorios Rubió, we are a company that trusts the people who are part of our organization, recognizes their professional value, and dedicates resources to ensure that a good working environment is maintained. We aim to foster opportunities, personal and professional development, and a good work-life balance.
As part of our strategic plan for business development and internationalization, Laboratorios Rubió has expanded by acquiring Fisiopharma (2021), OWL Metabolomics (2022), a controlling stake in Nutribrain (2024), and founded CIMA Sciences (2023) in the USA and Rubió Nutraceuticals (2023) in Italy. In 2021, we began expanding our production facilities to double our capacity.
We concentrate its investments on expanding production capacity and on R&D to lead in pharmaceutical innovation and global healthcare. In 2021, we started the expansion of our production facilities. These will allow us to double our capacity virtually. We also continue to invest in various R&D projects for both the European and US markets to lead in pharmaceutical innovation and global healthcare.
Investments (in thousands of €)
Two major areas of Pharmaceutical and In-vitro Diagnosis
and nutrition for special conditions.
Laboratorios Rubió’s business activity is structured into four major areas: Pharmaceutical, OTC, Metabolomics, and Diagnostics. Our extensive vademecum includes pharmaceutical products focused on therapeutic areas such as Rheumatology, Musculoskeletal system, Nephrology, Urology, Andrology, Digestive/Gastro, Central Nervous System, Gynecology, Radiotherapeutic Oncology, and Hepatology.
We manufacture and sell well-established pharmaceutical drugs with a solid reputation and introduce new products annually through our R&D and partnerships with third parties.
Our Metabolomics division focuses on liver research, R&D, and non-invasive diagnostic tests.
Our Diagnostics division offers in-vitro tests to determine lipoprotein fractions for cardiovascular risk and non-invasive diagnostic tools for assessing all lesional phases of MASLD.
The OTC business unit provides complete formulas for food supplements for osteoarticular and muscular health.
Created in 2014, this subsidiary acts as a “patent box” to boost the Laboratorios Rubió’s R&D&i department. Within this sphere of activity, the company’s number one strategy is based on expanding the lifecycle of its products, collaborating with new research programs whose goals tie in with the company’s own therapeutic goals, and establishing strategic alliances with research foundations in related fields.
Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), is one of Laboratorios Rubió’s investee companies, which specializes in developing in vitro diagnostic tests to improve cardiovascular assessment in high-risk patients.
A national company specializing in nutraceuticals aimed at musculoskeletal health, which will grow in the coming years both in products from other therapeutic areas and in other countries.
